Shanghai Bio-heart Biological Technology Co., Ltd.
2185.HKHKSEHealthcareBiotechnology
Latest quote
HK$2.085
−HK$0.015 · -0.71%
2185.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteBased in the People's Republic of China, Shanghai Bio-heart Biological Technology Co., Ltd. is a medical technology firm specializing in interventional cardiovascular devices. Its core business revolves around delivering bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies to address conditions like coronary artery diseases and persistent, uncontrolled high blood pressure. The company's product pipeline features Bioheart, a BRS system designed for percutaneous coronary interventions for coronary artery disease; Iberis 2nd, a multi-electrode RDN product candidate; and a sirolimus drug-eluting balloon catheter intended for managing in-stent restenosis. Furthermore, the company has partnered with Terumo (China) Investment Co., Ltd. to conduct clinical trials for Iberis 2nd. Shanghai Bio-heart Biological Technology Co., Ltd. was established in 2014 and maintains its headquarters in Shanghai, China.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Li Wang
- Listed since
- Dec 23, 2021
- Employees
- 65
Market position
Day range
Current HK$2.085
52-week range
Current HK$2.085
- Open
- HK$2.10
- Previous close
- HK$2.10
- Volume
- 351.4K
- 0.69× average
- Average volume
- 510.41K
- Average daily volume
- Market cap
- 491.44M HKD
- Beta
- 0.09
- Market reference 1
- 50-day average
- HK$2.446
- -14.76% below average
- 200-day average
- HK$4.4317
- -52.95% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 1.19B CNY
- P/E (TTM)
- -6.13×
- P/B (TTM)
- 0.97×
- P/S (TTM)
- 9.46×
- EV / EBITDA
- -22.76×
- Earnings yield
- -5.39%
- Free cash flow yield
- -5.76%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 17.17%
- Operating margin
- -159.11%
- Net margin
- -155.71%
- Return on equity
- -15.69%
- Return on assets
- -8.19%
- Return on invested capital
- -6.15%
Financial health
- Debt / equity
- 0.03×
- Current ratio
- 15.26×
- Altman Z-score
- -0.45
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 43.77M CNY | — | — | — | — |
| Cost of goods sold | 43.93M CNY | — | 23.6M CNY | 24.25M CNY | — |
| Gross profit | −157.81K CNY | — | −23.6M CNY | −24.25M CNY | — |
| Research and development | 58.15M CNY | 41.3M CNY | 111.74M CNY | 168.73M CNY | 214.23M CNY |
| Selling, general, and administrative | 11.53M CNY | 19.74M CNY | 16.09M CNY | 100.29M CNY | 195.42M CNY |
| Operating expenses | 69.68M CNY | 61.04M CNY | 164.62M CNY | 269.02M CNY | 409.65M CNY |
| Interest income | 1.96M CNY | 1.04M CNY | 4M CNY | 4.01M CNY | 287K CNY |
| Interest expense | 8.52M CNY | — | 578K CNY | 959K CNY | — |
| Depreciation and amortization | 17.71M CNY | 16.5M CNY | 16.41M CNY | 14.87M CNY | 8.77M CNY |
| Operating income | −69.84M CNY | −61.04M CNY | −164.62M CNY | −293.28M CNY | −409.65M CNY |
| Net income | −68.24M CNY | −87.94M CNY | −194.36M CNY | −237.5M CNY | −361.45M CNY |
Company facts updated Aug 24, 2026.
Earnings
- Latest EPS result
- -0.2
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
2185.HK peers
Continue in GoAI
Research 2185.HKresearch.disclaimer